Compass Therapeutics, Inc.CMPXEarnings & Financial Report
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
CMPX Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-15.8M
Net Profit
$-14.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.08
Compass Therapeutics, Inc. Q3 FY2025 Financial Summary
Compass Therapeutics, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-14.3M (down 36.0% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-14.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Compass Therapeutics, Inc. Quarterly Revenue & Net Profit History
Compass Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-14.3M | N/A |
| Q2 FY2025 | $0 | — | $-19.9M | N/A |
| Q3 FY2024 | $0 | — | $-10.5M | N/A |
| Q2 FY2024 | $850.0K | — | $-13.1M | -1538.4% |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $850000 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $155.6M | $149.2M | $116.7M | $231.3M |
| Liabilities | $9.5M | $10.8M | $23.5M | $21.6M |
| Equity | $146.1M | $138.4M | $93.2M | $209.6M |
Cash Flow
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-10.8M | $-11.1M | $-11.8M | $-10.8M |